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Exciting News From the clinic: anticancer drugs acting
on Bcl-2 proteins work!
The Manchester Cancer Research Centre (MCRC), which is
becoming the largest British center for clinical and preclinical
research on cancer, recently organized a high proﬁle
conference. Cell death was the major theme of the meeting,
which combined the contributions from world experts in cell
biology and clinical translation of novel antitumour drugs that
act on cell death pathways. For basic research scientists such
as me, it was fascinating to learn the incredible advances that
have been recently obtained in the clinical translation of new
‘proapoptotic’ drugs. It was also exciting to realize that so
much research lies ahead for the clariﬁcation of cellular and
biophysical aspects of these drugs, in particular for those
acting on the Bcl-2 family of proteins that regulate cell death.
Hence, successful clinical applications of drugs acting on
Bcl-2 proteins now stimulate renewed interests in the basic
science of Bcl-2 function, the perspectives of which I will
outline in this meeting report.
Discussion on how Bcl-2 proteins work together
The mainframe model of how Bcl-2 proteins regulate the key
event in cell death signaling, namely the piercing of
mitochondrial organelles (mitochondrial outer membrane
permeabilization, MOMP), was established at the beginning
of this century. Laboratories of the late Stanley Korsmeyer
and of the ever-sparkling Doug Green, who delivered the
opening lecture at the MCRC conference, contributed funda-
mental evidence supporting the model that has nowadays
entered textbooks. However, as soon as this mainframe
model was widely accepted, it generated a controversy that
remainsunsettledtodate.Thefollowingquestionsummarizes
the controversy: Are proteins of the Bcl-2 family such as Bid
and Bad equivalent in their proapoptotic capacity of inducing
MOMP? Although various deﬁnitions have been used at the
conference to describe the action of Bid and Bad, Bcl-2-binding
drugs such as ABT-737 from Abbot Laboratories (Abbott Park,
IL, USA) clearly act as antagonists, because they neutralize
antiapoptotic proteins such as Bcl-2 itself. ABT-737 and its
analogs were in fact designed to precisely mimic the BH3
domain of Bad, as elegantly presented by Saul Rosenberg at
the conference. The BH3domain corresponds to an amphipatic
a-helix representing the single region of sequence homology
that is present in all the proteins of the Bcl-2 family and is
essential for their reciprocal interaction. Bad is a typical
‘BH3-only’ protein because it contains only the BH3 domain of
structural similarity. The diversity of Bad and other BH3-only
proteins was discussed at the conference, but not enough to
resolve the controversy on how Bcl-2 proteins work.
Although generally considered to be a BH3-only protein,
Bid is in fact structurally and phylogenetically related to the
multi-domain subfamily of the Bcl-2 proteins, including all
the antiapoptotic members and the gatekeepers of MOMP,
Bax and its homologs. Of note, Bax and most multi-domain
Bcl-2 proteins share with Bid the property of interacting
with membrane lipids and detergents. In contrast Bad, Bim,
Puma, Noxa and other BH3-only proteins do not show
common structural features with the multi-domain proteins
of the family; therefore, they are Bcl-2 analogs, rather than
Bcl-2 homologs. Indeed, they do not interact with membrane
lipids andarealso unrelatedtothesubfamily ofBNIP3,anodd
type of proapoptotic proteins seemingly associated with
autophagic cell death. Autophagy is clearly involved in cancer
and offers promising targets for new antitumour drugs, as
presented by Eileen White at the conference.
Common structural and lipid-interacting properties may
explainwhyonlyBid,amongtheBH3-onlyproteins,iscapable
to catalytically activate Bax for inducing MOMP. Recent
reports showing that the BH3 domains of Bim and Puma also
elicit Bax activation may indicate additional reactions, which
do not match the catalytic activation produced by Bid. Indeed,
Bax binding of a stapled helix corresponding to the BH3
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hydrophobic cleft that is involved in the BH3-mediated
interactions among Bcl-2 proteins. This cleft forms the binding
site of ABT-737 and other Bcl-2-interacting drugs, which
mimic the action of BH3-only proteins and thus work as
general antagonists of antiapoptotic Bcl-2 proteins. Bid
constitutes an important exception to the generalization, as
it can also activate Bax directly to promote the membrane
perturbation leading to MOMP. By considering that Bax
activation can occur also in the absence of other Bcl-2
proteins, the details of this process remain unclear. More
research is thus needed to clarify how Bax becomes
activated, a central question in apoptosis research as
indicated in the presentations of Doug Green and Tony Letai.
Back to the bench: new approaches to clarify how Bcl-2
proteins and their drugs work
The availability of clinically effective, small molecule
BH3-mimetics such as ABT-737 will be exploited at the bench
of biochemistry laboratories, as simpliﬁed model systems
can effectively recapitulate the integrated action of Bcl-2
proteins on biological membranes. Besides an increasing
wealth of structural information, the study of Bcl-2 proteins has
remained mainly based on changes in antibody reactivity,
coupled to gel ﬁltration and crosslinking approaches for
detecting oligomers associated with Bax activation and
MOMP. Membrane effects have been increasingly studied
with liposomes mimicking the composition of mitochondrial
membranes, which contain the unique lipid cardiolipin. Speciﬁc
binding to cardiolipin has been documented for the caspase-
cleaved form of Bid (tBid) and appears to be fundamental for
the integrated membrane action of tBid and Bax; it may also
modulate the mitochondrial association of antiapoptotic
Bcl-2 proteins. However, cardiolipin may not be required for
the proapoptotic action of Bad, Bimandother BH3-onlyproteins.
Most approaches focused on the aqueous phase do not
produce accurate information on the protein dynamics at the
surface of the membrane, where the activation and reciprocal
interactionsofBcl-2proteinsoccur.Thesearethekeyreactions
of Bcl-2 proteins that we poorly understand, another problem
that has emerged attheconference.Thestandardassaybased
upon the leakage of probes trapped within monolamellar
liposomes cannot illuminate the details of how Bcl-2 proteins
dock onto the membrane surface and then penetrate the
external lipid layer. Consequently, we hardly know how Bcl-2
proteins ultimately induce MOMP. On the other hand, assays
normally used for measuring membrane fusion would be very
appropriate for evaluating the rate-limiting steps in the process
ofmembrane penetration byBcl-2 proteins suchas Bax.These
assays can be developed by studying rapid changes in the
ﬂuorescence of lipid probes embedded within the external layer
of liposomal membranes, an approach that I have pioneered
with Bid. Additional model systems could be devised by
using mixtures of aqueous and organic phases, such as
inverted micelles, in which appropriately labeled Bcl-2 proteins
could be monitored to penetrate and self-aggregate in the
milieu of the lipid membrane. The outlined approaches could
also elucidate the uncertainties regarding the cellular distri-
bution of Bcl-2 antagonists such as ABT-737. ABT-737 and
related drugs arelarge hydrophobicmoleculesthatresemblein
dimensions and some chemical properties like proportion of
hydrophilic surface, detergent-like lipids related to cardiolipin,
for instance lysophosphatidyl glycerol (Figure 1). They are thus
likely to enter cells following the constitutive pathways of lipid
trafﬁc that are used by natural lysolipids. In this unexplored
scenario, the drugs would then reach mitochondria after
membrane fusion with vesicles from the endocytic and other
compartments. Once incorporated within the outer mitochon-
drial membrane, how would the verylipophilic ABT-737 jump to
the BH3-binding pocket of antiapoptotic Bcl-2 proteins, which
normally protrudes in the aqueous phase of the cytosol? The
new approaches suggested here will provide an experimental
answer to this question, which was raised at the conference
and has crucial pharmacological importance. Eventually, it
will be possible to go back to the clinic with an advanced
knowledge of the cellular and membrane-target distribution of
Bcl-2 antagonist drugs. The pertinent information, acquired by
solid laboratory work of basic science, will be transferable to
implement clinical applications. And then the learning cycle will
be reversed: from the bench, back to the clinic! The theme for
a future MCRC conference, perhaps.
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Figure 1 Structural comparison of the Bcl-2 antagonist drug, ABT-737, with a
membrane lipid having detergent properties, 2-linoleyl-lyso-phosphatidyl-glycerol
(LysoPG), which is related to the mitochondria-speciﬁc lipid cardiolipin
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